Who owns VOR BIOPHARMA INC?
- Ticker: VOR
- CUSIP Number: 929033207
Tip: Access positions for across all investors
Analyze quarterly positions in Vor Biopharma with up to 7 years of data, all consolidated into one spreadsheet
Download as csv
Download as Excel
Top investors of Vor Biopharma stock
Who bought or sold VOR BIOPHARMA INC this quarter?
| Fund or Company Name | Shares Held | Valued At | Change in Shares | As Of | Actions |
|---|---|---|---|---|---|
| TCG Crossover Management | 5.7M | $97M | 100% | Mar 2026 |
|
| RA Capital Management | 5.4M | $96M | 0% | Mar 2026 |
|
| Fcpm Iii Services B.v. | 4.1M | $74M | 14% | Mar 2026 |
|
| VR Adviser | 3.0M | $54M | 56% | Mar 2026 |
|
| Frazier Life Sciences Management | 2.5M | $45M | 0% | Mar 2026 |
|
| Caligan Partners | 1.9M | $34M | 108% | Mar 2026 |
|
| Dr. Jeffrey R. Jay, M.D. | 1.8M | $31M | 28% | Mar 2026 |
|
| Paradigm Biocapital Advisors | 1.8M | $31M | 0% | Mar 2026 |
|
| FMR | 1.5M | $28M | -39% | Mar 2026 |
|
| Vanguard Capital Management | 1.4M | $26M | 100% | Mar 2026 |
|
| Marshall Wace | 1.2M | $21M | 100% | Mar 2026 |
|
| State Street Corporation | 1.1M | $20M | 1128% | Mar 2026 |
|
| BlackRock | 795k | $14M | 71% | Mar 2026 |
|
| Logos Global Management | 750k | $13M | 650% | Mar 2026 |
|
| Rosalind Advisors | 700k | $13M | 100% | Mar 2026 |
|
| Boothbay Fund Management | 556k | $9.9M | 100% | Mar 2026 |
|
| UBS Group | 488k | $8.7M | 67% | Mar 2026 |
|
| Braidwell | 467k | $8.3M | 100% | Mar 2026 |
|
| Susquehanna International | 409k | $7.3M | -70% | Mar 2026 |
|
| Geode Capital Management | 343k | $6.1M | 84% | Mar 2026 |
|
| Clearline Capital | 326k | $5.8M | 100% | Mar 2026 |
|
| Sphera Funds Management | 322k | $5.7M | -22% | Mar 2026 |
|
| Laurion Capital Management | 319k | $5.7M | 0% | Mar 2026 |
|
| Propel Bio Management | 315k | $5.6M | 100% | Mar 2026 |
|
| Goldman Sachs Group | 262k | $4.7M | 80% | Mar 2026 |
|
| Millennium Management | 259k | $4.6M | 15% | Mar 2026 |
|
| Vanguard Fiduciary Trust | 186k | $3.3M | 100% | Mar 2026 |
|
| Jump Financial | 173k | $3.1M | 100% | Mar 2026 |
|
| Tudor Investment Corporation | 153k | $2.7M | -9% | Mar 2026 |
|
| Citadel Advisors | 149k | $2.7M | -68% | Mar 2026 |
|
| Renaissance Technologies | 129k | $2.3M | 100% | Mar 2026 |
|
| Morgan Stanley | 117k | $2.1M | 310% | Mar 2026 |
|
| Bank of America Corporation | 113k | $2.0M | 100% | Mar 2026 |
|
| Axiom International Investors | 96k | $1.7M | 100% | Mar 2026 |
|
| Quadrature Capital | 77k | $1.4M | 186% | Mar 2026 |
|
| Jane Street | 76k | $1.4M | -28% | Mar 2026 |
|
| Northern Trust | 65k | $1.2M | 66% | Mar 2026 |
|
| Johnson & Johnson | 54k | $959k | 0% | Mar 2026 |
|
| Rafferty Asset Management | 51k | $901k | 100% | Mar 2026 |
|
| Brevan Howard Capital Management | 42k | $753k | 100% | Mar 2026 |
|
| Irenic Capital Management | 33k | $583k | 100% | Mar 2026 |
|
| Engineers Gate Manager | 27k | $480k | -5% | Mar 2026 |
|
| Squarepoint Ops | 26k | $455k | 38% | Mar 2026 |
|
| Sarissa Capital Management | 25k | $453k | 0% | Mar 2026 |
|
| Bollard | 24k | $428k | 0% | Mar 2026 |
|
| Charles Schwab Investment Management | 22k | $396k | 100% | Mar 2026 |
|
| ProFund Advisors | 22k | $393k | 100% | Mar 2026 |
|
| Scientech Research | 15k | $268k | 100% | Mar 2026 |
|
| Axq Capital | 15k | $268k | 100% | Mar 2026 |
|
| Independent Financial Group | 14k | $249k | 100% | Mar 2026 |
|
| Sei Investments | 14k | $245k | 100% | Mar 2026 |
|
| Vanguard Global Advisers | 13k | $230k | 100% | Mar 2026 |
|
| Winton Capital | 12k | $212k | 100% | Mar 2026 |
|
| Cannon Global Investment Management | 12k | $209k | 100% | Mar 2026 |
|
| Invesco | 12k | $207k | 100% | Mar 2026 |
|
| Diametric Capital | 10k | $180k | 100% | Mar 2026 |
|
| Group One Trading | 9.1k | $162k | 100% | Mar 2026 |
|
| China Universal Asset Management | 7.4k | $131k | 168% | Mar 2026 |
|
| Citigroup | 5.4k | $96k | 100% | Mar 2026 |
|
| Mirae Asset Global Etfs Holdings | 3.5k | $52k | 100% | Mar 2026 |
|
| Tower Research Capital | 3.5k | $62k | 100% | Mar 2026 |
|
| Bnp Paribas Arbitrage, Snc | 2.8k | $51k | 877% | Mar 2026 |
|
| Mirae Asset Global Investments | 2.2k | $39k | 164% | Mar 2026 |
|
| Gf Fund Management | 372.00 | $6.6k | 13% | Mar 2026 |
|
| Quantbot Technologies | 307.00 | $5.5k | 100% | Mar 2026 |
|
| Pnc Financial Services | 246.00 | $4.4k | 100% | Mar 2026 |
|
| Royal Bank of Canada | 199.00 | $3.8k | 100% | Mar 2026 |
|
| Barclays | 136.00 | $2.4k | -90% | Mar 2026 |
|
| Hanson McClain Advisors | 73.00 | $1.3k | 2333% | Mar 2026 |
|
| Parallel Advisors | 48.00 | $855.998400 | 100% | Mar 2026 |
|
| MAI Wealth Advisors | 40.00 | $714.000000 | 0% | Mar 2026 |
|
| Signature | 39.00 | $696.001800 | 100% | Mar 2026 |
|
| Ameritas Advisory Services | 37.00 | $659.998600 | 100% | Mar 2026 |
|
| Fortitude Family Office | 31.00 | $552.999700 | 100% | Mar 2026 |
|
| WPG Advisers | 21.00 | $374.999100 | 100% | Mar 2026 |
|
| SBI Securities | 3.00 | $54.000000 | 0% | Mar 2026 |
|
| Wells Fargo & Company | 1.00 | $18.000000 | 0% | Mar 2026 |
|
Who sold out of Vor Biopharma?
| Fund or Company Name | Date Sold | Shares Held | Valued At |
|---|---|---|---|
| Findell Capital Management | Dec 2025 | 231k | $3.0M |
| Ameriprise Financial | Dec 2025 | 163k | $2.1M |
| Belvedere Trading | Dec 2025 | 58k | $37k |
| Simplify Asset Management | Mar 2026 | 54k | $955k |
| Hudson Bay Capital Management | Dec 2025 | 26k | $345k |
| OMERS Administration Corporation | Dec 2025 | 21k | $271k |
| XTX Topco | Dec 2025 | 18k | $229k |
| Persistent Asset Partners | Dec 2025 | 11k | $141k |
| None | Dec 2025 | 11k | $141k |
| Susquehanna Portfolio Strategies | Dec 2025 | 10k | $134k |
| Chung Wu Investment Group | Dec 2025 | 8.3k | $109k |